<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Although <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> is a well-recognized complication of type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> and insulin treatment in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, less research exists on <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> in the large number of patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> who are treated with oral <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> agents </plain></SENT>
<SENT sid="1" pm="."><plain>OBJECTIVE: To identify predictors of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo>-related emergency department (ED) and outpatient visits in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We used the 2004-2008 MarketScan database to conduct a nested case-control analysis </plain></SENT>
<SENT sid="3" pm="."><plain>Cohort members were 18 years of age or older with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and taking an oral <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> agent at cohort entry </plain></SENT>
<SENT sid="4" pm="."><plain>We required 12 months or more of continuous enrollment in a noncapitated plan and excluded persons with type 1 or <z:hpo ids='HP_0009800'>gestational diabetes</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Within the cohort, we selected 11,375 cases (first outpatient hypoglycemic event) and 68,247 controls using 6:1 incidence density sampling </plain></SENT>
<SENT sid="6" pm="."><plain>A conditional logistic regression model estimated the adjusted odds ratios (AORs) and corresponding 95% confidence intervals of predictors </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Cases were more likely than controls to have <z:e sem="disease" ids="C0271672" disease_type="Disease or Syndrome" abbrv="">diabetic complications</z:e> and other comorbidity, and to be using the most <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> or other medications </plain></SENT>
<SENT sid="8" pm="."><plain>The presence of individual micro- and macrovascular complications of <z:mp ids='MP_0002055'>diabetes</z:mp> increased the relative rate of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>With no <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> drug therapy as the referent (within 30 days preceding the index date), insulin monotherapy (AOR 1.76; 95% CI 1.50 to 2.05) and insulin in combination with other oral <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> agents (AOR 1.80; 95% CI 1.65 to 1.97) had the highest relative rates of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> monotherapy (AOR 0.65; 95% CI 0.61 to 0.70), thiazolidinedione monotherapy (AOR 0.71; 95% CI 0.63 to 0.79), and dipeptidyl peptidase-4 inhibitor monotherapy (AOR 0.63; 95% CI 0.45 to 0.89) had decreased relative rates of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>Monotherapy with <z:chebi fb="0" ids="26831">sulfonylureas</z:chebi>, other injectable agents, meglitinides or Î±-glucosidase inhibitors was not predictive </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: Medications should be prescribed carefully for patients at high risk of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo>, particularly those with <z:mp ids='MP_0002055'>diabetes</z:mp> complications or those taking insulin alone or in combination </plain></SENT>
<SENT sid="13" pm="."><plain>Additional studies are needed to carefully examine the nature of the association between <z:mp ids='MP_0002055'>diabetes</z:mp>-related complications and <z:hpo ids='HP_0001988'>hypoglycemic episodes</z:hpo> </plain></SENT>
</text></document>